A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer
Phase of Trial: Phase II/III
Latest Information Update: 05 Oct 2017
At a glance
- Drugs Trametinib (Primary) ; Doxorubicin liposomal; Letrozole; Paclitaxel; Tamoxifen; Topotecan
- Indications Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms LOGS
- Sponsors GlaxoSmithKline
- 10 Jun 2017 Biomarkers information updated
- 13 May 2016 Status changed from suspended to recruiting.
- 09 Feb 2016 Status changed from recruiting to suspended, according to ClinicalTrials.gov record.